Everett E. Vokes to Combined Modality Therapy
This is a "connection" page, showing publications Everett E. Vokes has written about Combined Modality Therapy.
Connection Strength
3.182
-
Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. Semin Oncol. 2008 Jun; 35(3):251-61.
Score: 0.246
-
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
Score: 0.223
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res. 2004 Aug 01; 10(15):4922-32.
Score: 0.188
-
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. Lung Cancer. 2021 06; 156:68-71.
Score: 0.150
-
Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer. Oncol Rep. 2012 May; 27(5):1625-9.
Score: 0.079
-
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011 Aug 10; 29(23):3120-5.
Score: 0.076
-
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. Ann Oncol. 2011 Oct; 22(10):2304-9.
Score: 0.074
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.072
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
Score: 0.070
-
Chemoradiation for patients with advanced oral cavity cancer. Laryngoscope. 2010 Jan; 120(1):93-9.
Score: 0.069
-
PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009 May; 10(3):193-8.
Score: 0.065
-
Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol. 2009 Jan; 19(1):11-6.
Score: 0.064
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.063
-
Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol. 2008 Aug; 3(8):917-28.
Score: 0.062
-
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008 May 20; 26(15):2457-63.
Score: 0.061
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.061
-
Combining radiotherapy with systemic therapies. Clin Adv Hematol Oncol. 2008 Mar; 6(3):167-9.
Score: 0.060
-
Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007 Sep 10; 25(26):4118-26.
Score: 0.058
-
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 01; 25(13):1698-704.
Score: 0.057
-
The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007 Mar; 4(3):156-71.
Score: 0.056
-
The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007 Feb; 4(2):86-100.
Score: 0.056
-
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.053
-
Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer. 2005 Oct; 50 Suppl 1:S20-2.
Score: 0.051
-
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5045s-5050s.
Score: 0.050
-
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005 Mar-Apr; 11(2):140-6.
Score: 0.049
-
Current treatments and promising investigations in a multidisciplinary setting. Ann Oncol. 2005; 16 Suppl 6:vi25-vi30.
Score: 0.049
-
Concurrent chemoradiotherapy for head and neck cancer. Semin Oncol. 2004 Dec; 31(6):786-93.
Score: 0.048
-
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck. 2004 May; 26(5):447-55.
Score: 0.046
-
Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004 Feb; 18(1):81-90.
Score: 0.046
-
Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. Lung Cancer. 2003 Dec; 42 Suppl 1:S65-9.
Score: 0.045
-
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
Score: 0.045
-
Therapeutic options for laryngeal cancer. N Engl J Med. 2003 Nov 27; 349(22):2087-9.
Score: 0.045
-
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer. 2003 Aug; 41 Suppl 1:S115-21.
Score: 0.044
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.043
-
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
Score: 0.042
-
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. Oncologist. 2003; 8(4):350-60.
Score: 0.042
-
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002 Oct 15; 20(20):4191-8.
Score: 0.042
-
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer. 2002 Oct; 38(1):65-71.
Score: 0.041
-
Curative treatment for advanced head and neck cancer in the community: has the time come? Cancer J. 2002 Jul-Aug; 8(4):298-300.
Score: 0.041
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.038
-
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. Oncologist. 2001; 6 Suppl 1:25-7.
Score: 0.037
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.035
-
Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
Score: 0.022
-
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
Score: 0.022
-
Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. Lung Cancer. 2001 Sep; 33 Suppl 1:S85-9.
Score: 0.019
-
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer. Am J Clin Oncol. 2011 Aug; 34(4):356-61.
Score: 0.019
-
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2011 Nov; 22(11):2501-2507.
Score: 0.019
-
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep; 5(9):1382-90.
Score: 0.018
-
Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010 Jun; 95(3):308-11.
Score: 0.017
-
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009 Sep; 4(9):1117-25.
Score: 0.017
-
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
Score: 0.017
-
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2008 Oct; 134(10):1060-5.
Score: 0.016
-
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer. 2008 Oct; 62(1):92-8.
Score: 0.015
-
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91.
Score: 0.015
-
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer. J Thorac Oncol. 2008 Jan; 3(1):59-67.
Score: 0.015
-
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
Score: 0.015
-
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J Thorac Oncol. 2007 Jul; 2(7):645-51.
Score: 0.014
-
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):678-84.
Score: 0.014
-
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. Clin Lung Cancer. 2007 Jan; 8(4):268-72.
Score: 0.014
-
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):382-91.
Score: 0.013
-
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer. 2005 Jul; 7(1):47-53.
Score: 0.013
-
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
Score: 0.012
-
Cetuximab in cancers of the lung and head & neck. Semin Oncol. 2004 Feb; 31(1 Suppl 1):61-7.
Score: 0.011